Lori A. Leslie, MD

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Closing out her discussion on novel therapy for relapsed/refractory follicular lymphoma, Lori Leslie, MD, highlights unmet needs and considers future evolutions in the treatment paradigm.

Insight to the factors that help select optimal third-line treatment for patients with follicular lymphoma in the context of available novel therapies.

A comprehensive overview of the third-line treatment armamentarium for patients with relapsed/refractory follicular lymphoma.

Key opinion leader Lori Leslie, MD, sheds light on the optimal sequencing of therapy throughout multiple lines of follicular lymphoma.

An expert’s perspective on assessing response to therapy in follicular lymphoma and the parameters used to identify high-risk disease.

Expert hematologist-oncologist Lori Leslie, MD, provides insight to the incidence and prognosis of follicular lymphoma, highlighting a patient case of refractory disease.

Lori A. Leslie, MD, discusses the FDA approval of axicabtagene ciloleucel for second-line relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Lori A. Leslie, MD, discusses the current frontline treatment landscape in mantle cell lymphoma.

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).